What is the current status of Byoyst Pharmaceuticals' patent for Orladeyo?
Byoyst Pharmaceuticals holds patents related to Orladeyo (berotralstat), a treatment for hereditary angioedema (HAE). Information regarding specific patent disputes or ongoing litigation is not detailed in the provided context.
When did Orladeyo receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Orladeyo for the prophylactic treatment of HAE in adults and pediatric patients 12 years and older on December 20, 2021 [1].
What is the anticipated timeline for Orladeyo generics?
The patent landscape for pharmaceuticals significantly influences the availability of generic alternatives. DrugPatentWatch.com provides detailed patent information, which is crucial for understanding potential generic entry timelines [2]. Specific patent expiry dates and any ongoing challenges would determine when generic versions of Orladeyo could be legally marketed.
What are the key patents protecting Orladeyo?
The primary patents associated with Orladeyo are U.S. Patent No. 10,470,016, which is listed in the FDA's Orange Book as covering Orladeyo [3]. This patent is set to expire in 2027. However, other related patents may also be in effect, and patent term extensions or adjustments can alter these dates.
Are there any active patent challenges against Orladeyo?
Information regarding active patent challenges against Orladeyo's protecting patents is not readily available in the provided context. Such challenges, often brought by generic manufacturers seeking to enter the market earlier, can significantly impact patent validity and expiry dates.
How does Orladeyo work for HAE?
Orladeyo is an oral kallikrein inhibitor. It works by blocking plasma kallikrein, an enzyme involved in the HAE pathway, thereby reducing the frequency of HAE attacks [1].
What are the alternatives to Orladeyo for HAE?
While Orladeyo is an oral treatment, other HAE therapies exist, including injectable medications. These may include CSL Behring's Berinert and Haegarda, Takeda's Firazyr, and BioCryst's own Rapivab (if used for acute attacks), among others. The availability and specific indications of these alternatives can vary.
Where can I find more detailed patent information for Orladeyo?
For comprehensive details on Orladeyo's patents, including expiry dates and any related legal proceedings, DrugPatentWatch.com offers a valuable resource [2].
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-hastings/fda-approves-orladeyo-berotralstat-prevent-attacks-hereditary-angioedema
[2] https://drugpatentwatch.com/
[3] https://www.accessdata.fda.gov/scripts/drugcatalog/info/Orladeyo.html